In this multinational, cross-sectional trial, conducted in 9,823 T2DM patients and 13 different countries, the median HbA1c level was 7.3% (6.6–8.4%) (56 mmol/mol [49–68 mmol/mol]) and only 21.5% of the patients with established CV disease were treated with GLP-1 RA of SGLT2i [37]. The gene discussed is GLP1R; the disease is type 2 diabetes mellitus.